Document is current
Any future updates will be listed below
-
Authors
Martin-Broto, Javier https://orcid.org/0000-0001-7350-6916
Redondo, Andres
Moura, David S.
Valverde, Claudia
Morales, Jose Manuel
Lopez-Pousa, Antonio
Martinez-Trufero, Javier https://orcid.org/0000-0002-0997-2573
Gutierrez, Antonio
Díaz-Beveridge, Roberto
Luna, Pablo
Martinez-Marin, Virginia
Marcilla, David
Arribas, Ivan https://orcid.org/0000-0001-7600-8066
Ledesma, Patricio
Lopez-Martin, Jose Antonio https://orcid.org/0000-0001-7530-3207
Di Lernia, Davide
Zamora, Jorge
Hindi, Nadia https://orcid.org/0000-0002-5864-762X
-
Funding
Funding for this research was provided by:
Celgene (AX-CL-GEIS-007345)
- License Information
-
More Information
Article History
Received: 31 March 2022
Accepted: 10 October 2022
First Online: 21 October 2022
Competing interests
: J.M.-B. reports research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly and Company, Bayer, GSK, Novartis, Amgen, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, BMS, Pfizer, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Celgene, Novartis, Blueprint, Nektar, Forma, Amgen, and Daichii-Sankyo. D.S.M. reports institutional research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer and Pfizer, and personal fees from Tecnopharma, outside the submitted work. Nadia Hindi reports grants, personal fees and non-financial support from PharmaMar, personal fees from Lilly and Tecnopharma, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen, and Daichii-Sankyo. The remaining authors declare no competing interests.
